Prof. Eric Morand, Dean of Sub-Faculty of Clinical and Molecular Medicine at Monash University, and Head of Rheumatology at Monash Health, gives a presentation on ‘Specific Therapy for Systemic Lupus Erythematosus (SLE).’ He talks about new research in an article published in Feb24 from Monash, ‘Smith-specific regulatory T-cells that halt the progression of Lupus Nephritis’.
Prof. Morand explains why people with Lupus have their kidneys ‘attacked’, as opposed to people without Lupus.
The real breakthrough, he explains, is recognising that key factor in why healthy people don’t get get their kidneys ‘attacked’, and that is because they have Regulatory T-cells. Essentially, when you have a healthy immune system, your body switches “on” the cells that kill bacteria, and has the ability to then switch them “off” again with a T-Reg cell (a ‘slowing down’ cell).
In people with Lupus, the germ fighting cells do get activated, but have no “off” function, which results in autoimmune disease. This “off” function is what slows down an immune response in your body.
Watch Prof. Morand’s full presentation to learn more of this exciting research.
Julie shares her personal story of resilience, struggle and perseverance with Lupus. She has Systemic Lupus, Cutaneous Lupus and CNS Lupus. Julie was one of the first patients in Australia to receive the new Lupus treatment at the time, Anifrolumab. She talks about her journey on the treatment and shares her optimism with the results, and hope for people battling autoimmune conditions.
